224 related articles for article (PubMed ID: 15055565)
1. Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration.
Vogelson CT; Abelson MB; Pasquine T; Stephens DM; Gamache DA; Gross RD; Robertson SM; Yanni JM
Allergy Asthma Proc; 2004; 25(1):69-75. PubMed ID: 15055565
[TBL] [Abstract][Full Text] [Related]
2. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models.
Spangler DL; Abelson MB; Ober A; Gotnes PJ
Clin Ther; 2003 Aug; 25(8):2245-67. PubMed ID: 14512132
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model.
Greiner JV; Udell IJ
Clin Ther; 2005 May; 27(5):568-77. PubMed ID: 15978305
[TBL] [Abstract][Full Text] [Related]
4. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity.
Abelson MB; Spitalny L
Am J Ophthalmol; 1998 Jun; 125(6):797-804. PubMed ID: 9645717
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model.
Lanier BQ; Finegold I; D'Arienzo P; Granet D; Epstein AB; Ledgerwood GL
Curr Med Res Opin; 2004 Aug; 20(8):1227-33. PubMed ID: 15324525
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen-challenge model.
Brodsky M; Berger WE; Butrus S; Epstein AB; Irkec M
Eye Contact Lens; 2003 Apr; 29(2):113-6. PubMed ID: 12695716
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge.
Lanier BQ; Abelson MB; Berger WE; Granet DB; D'Arienzo PA; Spangler DL; Kägi MK
Clin Ther; 2002 Jul; 24(7):1161-74. PubMed ID: 12182260
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model.
Abelson MB; Welch DL
Acta Ophthalmol Scand Suppl; 2000; (230):60-3. PubMed ID: 11057354
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
Abelson MB; Greiner JV
Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis.
Abelson MB; Gomes PJ; Pasquine T; Edwards MR; Gross RD; Robertson SM
Allergy Asthma Proc; 2007; 28(4):427-33. PubMed ID: 17883910
[TBL] [Abstract][Full Text] [Related]
11. The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model.
Abelson MB; Lanier RQ
Acta Ophthalmol Scand Suppl; 1999; (228):53-6. PubMed ID: 10337434
[TBL] [Abstract][Full Text] [Related]
12. Duration of action of topical antiallergy drugs in a Guinea pig model of histamine-induced conjunctival vascular permeability.
Beauregard C; Stephens D; Roberts L; Gamache D; Yanni J
J Ocul Pharmacol Ther; 2007 Aug; 23(4):315-20. PubMed ID: 17803429
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge.
Fujishima H; Ohashi Y; Takamura E
Ann Allergy Asthma Immunol; 2014 Oct; 113(4):476-81. PubMed ID: 25163405
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model.
Spangler DL; Bensch G; Berdy GJ
Clin Ther; 2001 Aug; 23(8):1272-80. PubMed ID: 11558863
[TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model.
Deschenes J; Discepola M; Abelson M
Acta Ophthalmol Scand Suppl; 1999; (228):47-52. PubMed ID: 10337433
[TBL] [Abstract][Full Text] [Related]
16. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans.
Leonardi A; Abelson MB
Clin Ther; 2003 Oct; 25(10):2539-52. PubMed ID: 14667955
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge.
Abelson MB; Spangler DL; Epstein AB; Mah FS; Crampton HJ
Curr Eye Res; 2007 Dec; 32(12):1017-22. PubMed ID: 18085465
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.
Avunduk AM; Tekelioglu Y; Turk A; Akyol N
Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug.
Ohmori K; Hayashi K; Kaise T; Ohshima E; Kobayashi S; Yamazaki T; Mukouyama A
Jpn J Pharmacol; 2002 Apr; 88(4):379-97. PubMed ID: 12046981
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model.
Abelson MB
Ann Allergy Asthma Immunol; 1998 Sep; 81(3):211-8. PubMed ID: 9759796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]